Therapies targeting anti-TNFa when used as a monotherapy in patients with moderate–severe psoriasis are not associated with an increased risk of solid tumor or lymphoreticular malignancy; thus, patients with a history of cancer may in some circumstances receive a TNFa inhibitor without expectation of an increased risk of tumor recurrence [5]. Here, TNF is linked to psoriasis.